# Aprea Therapeutics, Inc.: filings

APRE · Nasdaq · CIK 1781983 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/apre.md) · [Financials](/companies/apre/financials.md) · [Filings](/companies/apre/filings.md) · [Insiders](/companies/apre/insiders.md)

## Reports and events: 146 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (4 152, 8-K 93, 3 28, 10-Q 21, CORRESP 11, SC 13G/A 11, SCHEDULE 13G/A 11, SC 13G 10, S-8 9, DEF 14A 8, SC 13D/A 8, UPLOAD 8, 10-K 7, EFFECT 7, 424B3 6, S-3 6, DEFA14A 5, SCHEDULE 13G 5, 424B5 4, ARS 4, S-1/A 4, SEC STAFF LETTER 4, PRE 14A 3, 10-K/A 2, S-3/A 2, SC 13D 2, 424B4 1, 424B7 1, 8-A12B 1, CERT 1, D 1, DRS 1, DRS/A 1, DRSLTR 1, FWP 1, S-1 1, S-1MEF 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-28 | 08:30 ET | [8-K](/filings/0001104659-26-102795.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-102795 |
| 2026-08-12 | 08:40 ET | [10-Q](/filings/0001104659-26-094544.md) | Quarterly report, period 2026-06-30 | 0001104659-26-094544 |
| 2026-08-12 | 08:35 ET | [8-K](/filings/0001104659-26-094542.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-094542 |
| 2026-07-23 | 16:05 ET | [8-K](/filings/0001104659-26-086254.md) | 3.01 Delisting notice | 0001104659-26-086254 |
| 2026-06-17 | 16:15 ET | [8-K](/filings/0001104659-26-075151.md) | 5.07 Shareholder vote results | 0001104659-26-075151 |
| 2026-05-13 | 06:46 ET | [10-Q](/filings/0001104659-26-059743.md) | Quarterly report, period 2026-03-31 | 0001104659-26-059743 |
| 2026-05-13 | 06:35 ET | [8-K](/filings/0001104659-26-059734.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-059734 |
| 2026-04-30 | 06:35 ET | [DEF 14A](/filings/0001104659-26-052044.md) | Proxy statement, period 2026-06-16 | 0001104659-26-052044 |
| 2026-04-01 | 08:45 ET | [8-K](/filings/0001104659-26-038258.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-038258 |
| 2026-03-30 | 17:30 ET | [8-K](/filings/0001104659-26-036821.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-036821 |
| 2026-03-16 | 08:30 ET | [10-K](/filings/0001104659-26-028068.md) | Annual report, period 2025-12-31 | 0001104659-26-028068 |
| 2026-03-16 | 08:15 ET | [8-K](/filings/0001104659-26-028046.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-028046 |
| 2026-02-18 | 08:30 ET | [8-K](/filings/0001104659-26-016797.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-016797 |
| 2026-01-29 | 16:16 ET | [8-K](/filings/0001104659-26-007988.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-007988 |
| 2026-01-23 | 16:45 ET | [8-K](/filings/0001104659-26-006267.md) | 3.01 Delisting notice | 0001104659-26-006267 |
| 2026-01-09 | 16:30 ET | [8-K](/filings/0001104659-26-002490.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-002490 |
| 2025-12-09 | 16:30 ET | [8-K](/filings/0001104659-25-119680.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-25-119680 |
| 2025-11-12 | 08:40 ET | [10-Q](/filings/0001104659-25-109867.md) | Quarterly report, period 2025-09-30 | 0001104659-25-109867 |
| 2025-11-12 | 08:35 ET | [8-K](/filings/0001104659-25-109860.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-109860 |
| 2025-10-24 | 08:35 ET | [8-K](/filings/0001104659-25-102004.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-102004 |
| 2025-10-15 | 08:05 ET | [8-K](/filings/0001104659-25-099534.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-25-099534 |
| 2025-09-08 | 07:45 ET | [8-K](/filings/0001558370-25-011909.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001558370-25-011909 |
| 2025-08-12 | 08:10 ET | [10-Q](/filings/0001558370-25-011152.md) | Quarterly report, period 2025-06-30 | 0001558370-25-011152 |
| 2025-08-12 | 08:05 ET | [8-K](/filings/0001558370-25-011149.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001558370-25-011149 |
| 2025-06-09 | 16:01 ET | [8-K](/filings/0001104659-25-057807.md) | 5.07 Shareholder vote results | 0001104659-25-057807 |
| 2025-05-14 | 08:10 ET | [10-Q](/filings/0001558370-25-007667.md) | Quarterly report, period 2025-03-31 | 0001558370-25-007667 |
| 2025-05-14 | 08:05 ET | [8-K](/filings/0001558370-25-007665.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001558370-25-007665 |
| 2025-04-22 | 16:05 ET | [DEF 14A](/filings/0001558370-25-005141.md) | Proxy statement, period 2025-06-05 | 0001558370-25-005141 |
| 2025-03-25 | 08:45 ET | [10-K](/filings/0001558370-25-003588.md) | Annual report, period 2024-12-31 | 0001558370-25-003588 |
| 2025-03-25 | 08:40 ET | [8-K](/filings/0001558370-25-003587.md) | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001558370-25-003587 |
| 2025-02-05 | 08:30 ET | [8-K](/filings/0001558370-25-000641.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001558370-25-000641 |
| 2025-01-13 | 08:00 ET | [8-K](/filings/0001558370-25-000155.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001558370-25-000155 |
| 2024-11-08 | 16:36 ET | [8-K](/filings/0001104659-24-115911.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001104659-24-115911 |
| 2024-11-07 | 08:38 ET | [8-K](/filings/0001558370-24-014768.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001558370-24-014768 |
| 2024-11-07 | 08:35 ET | [10-Q](/filings/0001558370-24-014767.md) | Quarterly report, period 2024-09-30 | 0001558370-24-014767 |
| 2024-10-23 | 09:00 ET | [8-K](/filings/0001558370-24-013486.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001558370-24-013486 |
| 2024-10-09 | 08:45 ET | [8-K](/filings/0001104659-24-107219.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-24-107219 |
| 2024-08-12 | 08:40 ET | [8-K](/filings/0001558370-24-011808.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001558370-24-011808 |
| 2024-08-12 | 08:35 ET | [10-Q](/filings/0001558370-24-011806.md) | Quarterly report, period 2024-06-30 | 0001558370-24-011806 |
| 2024-06-20 | 16:15 ET | [8-K](/filings/0001104659-24-073396.md) | 5.07 Shareholder vote results | 0001104659-24-073396 |
| 2024-06-17 | 08:45 ET | [8-K](/filings/0001558370-24-009225.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001558370-24-009225 |
| 2024-05-14 | 08:40 ET | [8-K](/filings/0001558370-24-008070.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001558370-24-008070 |
| 2024-05-14 | 08:35 ET | [10-Q](/filings/0001558370-24-008069.md) | Quarterly report, period 2024-03-31 | 0001558370-24-008069 |
| 2024-04-25 | 07:00 ET | [DEF 14A](/filings/0001558370-24-005678.md) | Proxy statement, period 2024-06-20 | 0001558370-24-005678 |
| 2024-04-10 | 16:15 ET | [8-K](/filings/0001558370-24-004927.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001558370-24-004927 |
| 2024-03-26 | 08:15 ET | [8-K](/filings/0001558370-24-003887.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001558370-24-003887 |
| 2024-03-26 | 07:45 ET | [10-K](/filings/0001558370-24-003886.md) | Annual report, period 2023-12-31 | 0001558370-24-003886 |
| 2024-03-12 | 16:31 ET | [8-K](/filings/0001104659-24-033494.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-24-033494 |
| 2024-02-06 | 17:01 ET | [8-K](/filings/0001558370-24-000818.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001558370-24-000818 |
| 2024-02-02 | 16:26 ET | [8-K](/filings/0001104659-24-010057.md) | 2.02 Results of operations | 0001104659-24-010057 |

Page 1 of 3. [Older](/companies/apre/filings.md?page=2)
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:15 ET. No prices; not investment advice.